Figure 1.
TP53 mutations correlate with worse outcomes after CART19 treatment. (A-B) Kaplan-Meier plots of OS (A) and EFS (B) from the day of first tisagenlecleucel infusion, stratified for the presence of TP53 mutations. Groups were compared using a log-rank test. ns, nonsignificant; ∗∗∗, P-value < 0.001.

TP53 mutations correlate with worse outcomes after CART19 treatment. (A-B) Kaplan-Meier plots of OS (A) and EFS (B) from the day of first tisagenlecleucel infusion, stratified for the presence of TP53 mutations. Groups were compared using a log-rank test. ns, nonsignificant; ∗∗∗, P-value < 0.001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal